# Lunit and Summit Therapeutics partner to use AI for tumor microenvironment analysis

> The companies will apply Lunit's SCOPE IO AI platform to H&E slides to aid biomarker work for Summit's ivonescimab immuno‑oncology programs.

Oossa · 2026-10-24 · https://oossa.com/en/lunit-and-summit-therapeutics-partner-to-use-ai-for-tumor-microenvironment-analy

Lunit Inc. and Summit Therapeutics announced a research agreement to evaluate Lunit’s AI‑powered pathology platform, SCOPE IO, on hematoxylin‑eosin whole‑slide images. The work will focus on extracting quantitative tumor microenvironment features to support biomarker discovery and patient selection for Summit’s bispecific antibody ivodescimab. Both firms say the analysis could provide scalable insights from routine tissue samples without extra stains. The collaboration is for research use only and does not involve clinical outcomes.

## The facts

- Agreement announced on Oct 24, 2026
- Platform: Lunit SCOPE IO; drug: Summit’s ivonescimab (PD‑1/VEGF bispecific)

## Why it matters

If successful, the AI analysis could help drug developers pinpoint which patients are most likely to benefit from ivonescimab.

## Sources & references

1. [Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development](https://www.prnewswire.com/news-releases/lunit-and-summit-therapeutics-announce-agreement-to-apply-ai-powered-scope-io-platform-for-tumor-microenvironment-analysis-in-immuno-oncology-development-302918571.html) – PR Newswire RSS, 2026-10-24

Last updated: 2026-10-24